Monthly Archives: August 2017

Oncotarget:A Multidisciplinary Journal With Scientific Reseach On Cancer And More

Oncotarget is a weekly, online, open-access, peer-reviewed medical journal that provides in-depth articles, papers and research information on all areas of oncology. Founded in 2010, it is published by Impact Journals. Noted cancer researchers and professors Mikhail Blagosklonny and Andrei V. Gudkov are Oncotarget’s editors-in-chief. Abstracted and indexed in Scopus, Science Citation Index Expanded, BIOSIS Previews and Medicus/MEDLINE/PubMed, Journal Citation Reports gives the journal an Impact factor of 5.168. Oncotarget has an online archive of its articles, however, each issue can also be printed on special demand.The term “oncotarget” covers all of the molecules, cellular functions and pathways common in cancer and aging, cancer cells and microbes, lymphocytes and neurons as well as neurodegeneration and atherosclerosis. Oncotarget’s online popularity is continually rising. This is due in part to its insightful, punctual, constructive, multiple peer-review process. This helps authors to increase their research’s impact.

The mission of the multidisciplinary journal is to make the results of scientific research being cone worldwide rapidly and widely available. Oncotarget also aims to eliminate the barriers between specialties and link the different areas of biomedical science. The publication also fosters applications of both basic and clinical science to help fight disease.Guided by the leadership of some of the world’s most prominent scientists, Oncotarget helps all researchers to be able to contribute to scientific progress. The ultimate goal is life without disease. The scientific community has so readily embraced the publication that Oncotarget has now launched sections on topics beyond oncology. The journal now accepts papers on Aging, Autophagy, Cardiology, Cell Biology, Cell Diseases, Chromosome, Endocrinology, Immunology, Metabolism, Neuroscience, Pathology, Pharmacology, Stem Cell and many other areas.

Oncotarget editorial board members Nobel prize winner Andrew Schally and former Cancer Research editor-in-chief Carlo M. Croce have had a combined 37 papers published in Oncotarget. Since 2013, Alexander Varshavsky, Bert Vogelstein, Stephen J. Elledge and Michael N. Hall, all members of Oncotarget/Oncoscience/Gerotarget, have won the Breakthrough Prize, the highest prize for scientific research.The authors give permission for anyone to copy, download, distribute, reprint, reuse or modify any articles that is published in Oncotarget. However, the original authors of the articles as well as its source must be properly cited. This policy is designed to aid in the dissemination of the information contained in the publication. This helps to give as many people as possible the opportunity to learn from the material.

Vijay Eswaran: Successful Business Mogul and Founder of the QI Group of Companies

Vijay Eswaran is the Executive Chairman and a co-founder of the QI Group of Companies, a business empire that’s becoming a great force in today’s corporate world. Born in 1960 in Malaysia, Vijay did his undergraduate and obtained a degree in socioeconomics from the London School of Economics in 1984.

After that, he moved to the United States where he did his MBA at Illinois University. It is during this period that he got introduced to multi-level marketing and harnessed entrepreneurial skills. He worked for several high-profile firms before founding the QI Group of Companies in 1998.

Vijay and the QI Group

The successful businessman partnered with Joseph Bismark to found the QI Group which has its headquarters in Hong Kong. The QI Group is an e-commerce conglomerate that has operations in various sectors, which include, direct selling, corporate investments, lifestyle and leisure, luxury and collectables, telecommunications, and property management.

The firm has recently ventured into education with the establishment of a university in Malaysia. This institution has created over 1,000 job opportunities, and it possesses a customer base of over five million across nearly 120 countries.

The success of the QI Group of companies can be attributed to the penetration of the e-commerce sales through direct sales. The company has grown from a small start-up to a large corporation with regional offices in Hong Kong, Singapore, Malaysia, and Thailand. Learn more about Kevin Seawright: http://www.qigroup.com/2013/11/vijay-eswaran-makes-ceo-of-the-year/ and http://skyscrapersports.com/3-years-nycfc-owners-man-city-vijay-eswarans-qnet-extend-partnership/

It has a presence in more than 30 countries through a broad range of subsidiary companies. The QI Group of Companies is worth more than $500 million, and it continues to dominate the business world, particularly in telecommunication and direct sales.

Vijay’s Achievements

The conception of the QI Group remains Vijay’s greatest achievement in the corporate sphere. His continued leadership in the firm has seen the company grow and expand its operations across the globe. Vijay Eswaran is also passionate about philanthropy and has demonstrated this through various activities.

As part of his corporate social responsibility, he established the Raise Yourself to Help Mankind (RYTHM) Foundation. He has also been involved in various initiatives and projects that focus on community development, culture, and the environment.

Marc Sparks on Venture Capital

Marc Sparks is a business owner and strong supporter of venture capital. He believes that venture capital is one of the best ways to make a positive impact in the world. Learn more: http://thebrotalk.com/bro-recommendations/dallas-entrepreneur-marc-sparks-spills-must-visit-list-wineries-dfw/

 

A lot of small business owners have great ideas, but they lack the proper capital to get started. Marc Sparks has started a variety of companies, and he has the experience that young business owners need. He now spends a lot of his time working on venture capital projects with his team. Learn more: http://www.marcsparks.com/

 

 

Marc Sparks

 

There are many people who are excited about the future of venture capital. With more online options than ever before, this is a great way to raise money in a business. Marc Sparks was not always interested in this area.

 

He started out in the world of business as someone who had little experience or funding. However, he had a dream to make a positive impact on his local community in Dallas. He loves to mentor young business owners who need additional help.

 

Marc Sparks has always written a lot of content on starting and operating a new business. With all of his experience, business owners love working with him.

 

 

The Importance of Capital

 

Starting a new business is never easy. One of the biggest issues faced by business owners is getting enough capital for their investment projects.

 

Marc Sparks loves to listen to business owners pitch their ideas to him. If he invests in a business, he will get a piece of the equity. He has worked in this field for several years, and during that time he has helped dozens of companies get started. He is excited about all of the potential projects that he is going to work on in the coming years. Learn more: https://classroomvoices.org/marc-sparks-risk-taker-in-and-out-of-business/

 

Marc Sparks is a great example of the impact that one person can make on others.

 

Jason Hope – Contributing to the Society through his Vast Resources and Knowledge

Jason Hope is a firm believer in the fact that technology would continue to shape the future as it has shaped our present. He is one of the most influential businessmen in the State of Arizona and a highly successful serial entrepreneur. Jason Hope has made smart investments in many of the new tech businesses, which have gone on to become a full-fledged technology company and market leaders in their niche. Jason Hope has worked hard to become successful and is an inspiration to the many young entrepreneurs in the State of Arizona as well in the rest of the country. As a self-proclaimed futurist, he believes that the future would change drastically due to the evolving technology.

One of the technologies he believes that would take over the world is the Internet of Things technology. The Internet of Things technology is all about connecting different gadgets, devices, and appliances in a coordinated manner. The devices that would be connected locally would be able to exchange information and work collectively towards completing one particular task efficiently and quickly. Many of the companies and industries are conducting broad scale research on how the internet of things can be useful for their business and whether it would help save time and money as many tech experts claim it will.

The popularity of the internet of things technology has reached new heights already in the tech circle. The aviation industry is already using the internet of things technology to know if there are any problems with their engine or other parts of their body. It has helped considerably in reducing the repair time and also improved accuracy. The technicians can figure very quickly if there are any problems with the airline and if anything needs repair to learn more: https://www.crunchbase.com/person/jason-hope#/entity click here.

Jason Hope has helped in ways more than one to contribute to the world of technology by funding new tech companies and sharing his ideas with many others and through his blogs. He also supports many local communities and funds independent research, especially the ones conducted by the SENS Research Foundation on anti-aging and finding ways to increase the average life span of human beings.

Curing Rare Diseases with Amicus Therapeutics

Amicus Therapeutics, Inc. is a leading new frontier global biotechnology company based in Cranbury, New Jersey. This innovative company researches new discovery findings, the development, and adopting therapies for devastating rare and orphan diseases. Amicus Therapeutics has a vigorous line of one-of-a-kind small molecules called ‘pharmacological chaperones.’ The chaperones provide dual-treatment to bind, stabilize and increase the activity of a patient’s own deformed enzymes to potentially improve enzyme replacement therapy outcome.

 

Amicus Therapeutics, Inc., research and development processes began as a result of Megan Crowley, who was diagnosed with Pompe disease which she had been suffering with since the age of one. Pompe is a progressive muscle and respiratory weakening disease with a high mortality rate. Megan’s father, John Crowley is now the CEO of this biotechnology company which has a pipeline of therapies for human genetic diseases like his daughter has. Mr. Crowley is determined to find a cure for his daughter and many others who suffer from rare, unexplored diseases (https://www.glassdoor.com/Reviews/Amicus-Therapeutics-Reviews-E26068.htm). His quest has made Amicus Therapeutics a leader for the drug industry and has made them champions in the development of new medical treatments and programs.

 

Fabry is also an early age disease that affects millions around the world, just like the Pompe disease. Fabry disease leads to progressive, irreversible organ damage, typically involving the nervous, cardiac, and renal systems, as well as multiple other tissues. Both diseases require daily medical assistance to manage and control the complications of these devastating diseases affecting multiple organ systems. To find a cure for the Fabry disease, the Pompe disease, and other chronic diseases, Amicus Therapeutics is investigating enzyme replacement therapy, influencing chaperone advanced replacement therapy, taking a lead in the clinical development of topical medicine to treat genetic connective tissue disorders, including investigating many other scientific first treatments and discovery programs.

 

Amicus Therapeutics is leading the fight in developing a topical therapy for the treatment of lesions and blisters that appear on the skin and in some cases on the lining of other body organs. This rare, chronic disease is known as Epidermolysis Bullosa. Epidermolysis Bullosa can potentially become disfiguring, and in some cases fatal. Amicus Therapeutics has also taken the lead recently in promising finds for the underlying cause of muscle damage and weakness in Pompe patients. This pioneering company has a three-fold promise, which is to remain at the forefront of therapies for rare and orphan diseases, to build long-term value for stakeholders and to foster teamwork and respect for each individual’s contribution.

facebook-icon-preview-1-400x400